ADVFN Logo ADVFN
Donnée du Marché
Actualité
Outils
Donnée du Marché
Discover

Hot Features

Follow Feed

Rester connecter avec les traders et investisseurs dans notre communauté Follow Feed.

Flux des Options

Explorez des données complètes sur les options et utilisez les filtres avancés avec Options Flow.

Moniteur

Organisez et surveillez vos d'actions et actifs avec le Moniteur.
Se connecter Premium IconPremium Help Menu
CAC 40
7 914,65
-0,88%
Dow Jones
38 226,45
0,85%
DAX
17 896,50
-0,14%
Brent Oil
83,555
0,02%
Bitcoin
59 300,69
1,83%
Registration Strip Icon for charts Inscrivez-vous pour des graphiques en temps réel, des outils d'analyse et des prix.
S'inscrire
  1. Accueil
  2. Investir
  3. Actions
  4. Etats-Unis
  5. NASDAQ
  6. Syros Pharmaceuticals Inc (SYRS)

  7. Syros Pharmaceuticals Inc (SYRS) Actualités

SYRS Syros Pharmaceuticals Inc

5,38
-0,06 (-1,10%)
Dernière mise à jour : 21:44:02
Retardé de 15 minutes
Nom Action Symbole Action Marché Type
Syros Pharmaceuticals Inc SYRS NASDAQ Action ordinaire
  Variation Action Variation Action% Cours Dernier Dernier échange
Upgrade Icon
-0,06 -1,10% 5,38 21:44:02
Ouverture Plus Bas Plus Haut Prix de clôture Clôture Veille
5,53 5,31 5,64 5,44
plus d'informations sur les cotations »

Actualités Recentes

Date Heure Source Titre
09/4/202413:00BWSyros Receives Fast Track Designation from the FDA for..
02/4/202422:30BWSyros Reports Inducement Grants Under Nasdaq Listing Rule..
27/3/202412:30BWSyros Reports Fourth Quarter and Full Year 2023 Financial..
27/3/202411:57IHMARKETNEWSU.S. Stock Index Futures Point to a Rebound, Oil See..
25/3/202412:00BWSyros Announces Completion of Enrollment of 190 Patients..
20/3/202412:00BWSyros to Report Fourth Quarter and Full Year 2023 Financial..
27/2/202413:00BWSyros to Participate in TD Cowen 44th Annual Health Care..
15/2/202402:56EDGAR2Form SC 13G - Statement of acquisition of beneficial..
14/2/202402:22EDGAR2Form SC 13G/A - Statement of acquisition of beneficial..
14/2/202401:02EDGAR2Form SC 13G/A - Statement of acquisition of beneficial..
14/2/202400:59EDGAR2Form SC 13G/A - Statement of acquisition of beneficial..
08/1/202413:06EDGAR2Form 8-K - Current report
08/1/202413:00BWSyros Highlights Anticipated 2024 Milestones to Deliver on..
02/1/202422:15EDGAR2Form SC 13G - Statement of acquisition of beneficial..
26/12/202323:19EDGAR2Form SC 13D/A - General statement of acquisition of..
19/12/202322:59EDGAR2Form 8-K - Current report
19/12/202322:53EDGAR2Form 424B5 - Prospectus [Rule 424(b)(5)]
19/12/202313:27BWSyros Announces Pricing of $45.0 million Underwritten..
14/12/202322:24EDGAR2Form 4 - Statement of changes in beneficial ownership of..
12/12/202322:12EDGAR2Form 144 - Report of proposed sale of securities
08/12/202322:23EDGAR2Form 4 - Statement of changes in beneficial ownership of..
06/12/202322:00EDGAR2Form 144 - Report of proposed sale of securities
06/12/202313:05EDGAR2Form 8-K - Current report
06/12/202313:00BWSyros Announces Encouraging Initial Data from Randomized..
05/12/202323:28EDGAR2Form 4 - Statement of changes in beneficial ownership of..
21/11/202313:30BWSyros to Participate in Upcoming Investor Conferences
14/11/202313:30BWSyros Reports Third Quarter 2023 Financial Results and..
14/11/202312:47EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
07/11/202313:30BWSyros to Report Third Quarter 2023 Financial Results on..
02/11/202321:53EDGAR2Form 4 - Statement of changes in beneficial ownership of..
02/11/202321:52EDGAR2Form 4 - Statement of changes in beneficial ownership of..
02/11/202321:52EDGAR2Form 4 - Statement of changes in beneficial ownership of..
02/11/202321:51EDGAR2Form 4 - Statement of changes in beneficial ownership of..
20/10/202322:15EDGAR2Form SC 13D - General statement of acquisition of beneficial..
02/10/202314:49EDGAR2Form 8-K - Current report
02/10/202314:45BWSyros Announces Planned CEO Leadership Transition and..
07/9/202322:30BWSyros Reports Inducement Grants Under Nasdaq Listing Rule..
11/8/202322:30EDGAR2Form 8-K - Current report
08/8/202313:30BWSyros Reports Second Quarter 2023 Financial Results and..
08/8/202312:53EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
04/8/202322:30BWSyros Reports Inducement Grants Under Nasdaq Listing Rule..
02/8/202322:21EDGAR2Form 4 - Statement of changes in beneficial ownership of..
01/8/202313:30BWSyros to Report Second Quarter 2023 Financial Results on..
31/7/202322:12EDGAR2Form 144 - Report of proposed sale of securities
21/7/202322:36EDGAR2Form 8-K - Current report
19/7/202302:27EDGAR2Form 4 - Statement of changes in beneficial ownership of..
17/7/202322:00EDGAR2Form 144 - Report of proposed sale of securities
05/7/202322:30BWSyros Reports Inducement Grants Under Nasdaq Listing Rule..
08/6/202313:30BWSyros to Present at Sidoti June 2023 Virtual Small-Cap..
01/6/202322:30BWSyros Reports Inducement Grants Under Nasdaq Listing Rule..

Dernières Valeurs Consultées

NASDAQ
SYRS
Syros Pharmaceuticals
Delayed Upgrade Clock
ADVFN Logo

France
Société
Entreprise
Popular
Obtenir l'application

Assistance: support@advfn.fr

En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales

© 2024 ADVFN PLC - Tous droits réservés